DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Chris Jones, Molina Das et al.|Cancer Discovery|2021Cited by 35
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens et al.|Journal of Clinical Oncology|2024Cited by 25
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C. Gray, Lucas Moreno, Rebekah Weston et al.|Journal of Clinical Oncology|2025Cited by 8
Figure 4 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial InhibitionElisa Izquierdo, Chris Jones, Diana Carvalho et al.|Unknown|2025Cited by 0